(Q39199053)

9 September 2017

Effect of lanreotide on polycystic liver and kidneys in autosomal dominant polycystic kidney disease: an observational trial (English)

1 reference

autosomal dominant polycystic kidney disease

9 September 2017

0 references

autosomal dominant polycystic kidney

1 reference

Tom J G Gevers

1

1 reference

9 September 2017

Jeroen C Hol

2

1 reference

9 September 2017

René Monshouwer

3

1 reference

9 September 2017

Helena M Dekker

4

1 reference

9 September 2017

Jack F M Wetzels

5

1 reference

9 September 2017

Joost P H Drenth

6

1 reference

9 September 2017

1 December 2014

1 reference

9 September 2017

1 reference

9 September 2017

35

1 reference

9 September 2017

1607-1614

1 reference

9 September 2017

5

1 reference

Hepatic cysts in autosomal dominant polycystic kidney disease

9 September 2017

1 reference

Evaluating health-related quality of life in patients with polycystic liver disease and determining the impact of symptoms and liver volume.

21 January 2018

1 reference

Polycystic liver disease: an overview of pathogenesis, clinical manifestations and management

21 January 2018

1 reference

Medical and surgical treatment options for polycystic liver disease

21 January 2018

1 reference

Somatostatin analogues for treatment of polycystic liver disease

21 January 2018

1 reference

Systematic review: the pathophysiology and management of polycystic liver disease

21 January 2018

1 reference

Somatostatin analogues reduce liver volume in polycystic liver disease

21 January 2018

1 reference

Reducing polycystic liver volume in ADPKD: effects of somatostatin analogue octreotide

21 January 2018

1 reference

Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease

21 January 2018

1 reference

Safety and efficacy of long-acting somatostatin treatment in autosomal-dominant polycystic kidney disease

21 January 2018

1 reference

Lanreotide reduces the volume of polycystic liver: a randomized, double-blind, placebo-controlled trial.

21 January 2018

1 reference

Effect of longacting somatostatin analogue on kidney and cyst growth in autosomal dominant polycystic kidney disease (ALADIN): a randomised, placebo-controlled, multicentre trial.

21 January 2018

1 reference

Young women with polycystic liver disease respond best to somatostatin analogues: a pooled analysis of individual patient data

21 January 2018

1 reference

Rationale and design of the RESOLVE trial: lanreotide as a volume reducing treatment for polycystic livers in patients with autosomal dominant polycystic kidney disease

21 January 2018

1 reference

A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group

21 January 2018

1 reference

Unified criteria for ultrasonographic diagnosis of ADPKD.

21 January 2018

1 reference

Evaluation of a gastrointestinal symptoms questionnaire

21 January 2018

1 reference

EuroQol--a new facility for the measurement of health-related quality of life

21 January 2018

1 reference

Renal hemodynamic effects of somatostatin are not related to inhibition of endogenous insulin release

21 January 2018

1 reference

Rationale and design of the DIPAK 1 study: a randomized controlled clinical trial assessing the efficacy of lanreotide to Halt disease progression in autosomal dominant polycystic kidney disease

21 January 2018

1 reference

The long-term outcome of patients with polycystic liver disease treated with lanreotide.

21 January 2018

1 reference

Somatostatin analogs and gallstones: a retrospective survey on a large series of acromegalic patients.

21 January 2018

1 reference

Cyst infections in patients with autosomal dominant polycystic kidney disease

21 January 2018

1 reference

Somatostatin analog therapy for severe polycystic liver disease: results after 2 years

21 January 2018

1 reference

Comparison of phenotypes of polycystic kidney disease types 1 and 2. European PKD1-PKD2 Study Group

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/LIV.12726

1 reference

9 September 2017

1 reference